Cat. No. | Product name | CAS No. |
DC5037 |
BMS-536924
Featured
BMS-536924 is an ATP-competitive IGF-1R inhibitor with IC50 of 100 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. |
468740-43-4 |
DC8482 |
CAY10415(MSDC-0160)
Featured
CAY10415 is a potent, antidiabetic drug of the TZD structural class. |
146062-49-9 |
DC9754 |
NT-157
Featured
NT157 is a selective inhibitor of IRS-1/2, IC50 values at sub-micromolar doses (ranging from 0.3 to 0.8 μM) . |
1384426-12-3 |
DC41861 |
S961 acetate
S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively. |
|
DC42043 |
GIP (1-30) amide, porcine
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). |
134846-93-8 |
DC42044 |
GIP (3-42), human
GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo. |
1802086-25-4 |
DC44220 |
GIP, human TFA
GIP, human TFA is thought to act as an inhibitor of gastric functions. GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a weak inhibitor of gastric acid secretion and a potent stimulator of insulin post meals. |
|
DC44221 |
GIP (1-30) amide, porcine TFA
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin. |
|
DC45692 |
DA-JC4
DA-JC4 is a dual GLP-1/GIP receptor agonist can be used for the research of neurological disease and insulin signaling pathways. |
2315504-40-4 |
DC47979 |
HNMPA
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities |
132541-52-7 |
DC48362 |
OI338
OI338 is an orally available, ultralong-acting insulin analogue. |
|
DC49413 |
Insulin glargine
Insulin glargine is a long-acting insulin analog. Insulin glargine can be used for the diabetes mellitus. |
160337-95-1 |
DC50118 |
HNMPA-(AM)3
HNMPA-(AM)3 is a cell-permeable and selective insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis. |
120944-03-8 |
DC50119 |
AVJ16
AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes. |
|
DC71030 |
Demethylasterriquinone B1
Demethylasterriquinone B1 is a selective insulin receptor activator. Demethylasterriquinone B1 stimulates tyrosine phosphorylation of the IR β subunit, and the activation of PIK3 and AKT. |
78860-34-1 |
DC71094 |
NT219
NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases. |
1198078-60-2 |
DC72496 |
CMX-2043
CMX-2043 is a novel analogue of α-Lipoic Acid. CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model. |
910627-26-8 |